trending Market Intelligence /marketintelligence/en/news-insights/trending/ibTVXYlKrW-cUVAr6wH9mw2 content esgSubNav
In This List

US FDA clears CytomX's investigational new drug application for cancer drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA clears CytomX's investigational new drug application for cancer drug

The U.S. FDA cleared CytomX Therapeutics Inc.'s investigational new drug application for its lead program CX-072 for the treatment of cancer.

CytomX plans to immediately initiate a clinical study and open clinical sites to support patient enrollment.

The clinical study will include phase 1/2 trials evaluating CX-072 as monotherapy and in combination with Yervoy or Zelboraf in patients with metastatic or locally advanced unresectable solid tumors or lymphomas.

Clinical data from the study is expected in late 2017 and throughout 2018.